These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 2865029)

  • 1. Ultra-short-acting beta-blockade: a comparison with conventional beta-blockade.
    Reilly CS; Wood M; Koshakji RP; Wood AJ
    Clin Pharmacol Ther; 1985 Nov; 38(5):579-85. PubMed ID: 2865029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics and onset of action of esmolol in anesthetized dogs.
    Quon CY; Gorczynski RJ
    J Pharmacol Exp Ther; 1986 Jun; 237(3):912-8. PubMed ID: 2872328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with esmolol, a short-acting beta-adrenergic blocker in cardiac arrhythmias and myocardial ischemia.
    Sung RJ; Blanski L; Kirshenbaum J; MacCosbe P; Turlapaty P; Laddu AR
    J Clin Pharmacol; 1986 Mar; 26(S1):A15-A26. PubMed ID: 2870082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary reactivity to methacholine during beta-adrenergic blockade: propranolol versus esmolol.
    Tobias JD; Sauder RA; Hirshman CA
    Anesthesiology; 1990 Jul; 73(1):132-6. PubMed ID: 1972872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-receptor antagonism does not fully explain esmolol-induced hypotension.
    Deegan R; Wood AJ
    Clin Pharmacol Ther; 1994 Aug; 56(2):223-8. PubMed ID: 7914845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Esmolol infusion versus propranolol infusion: effects on heart rate and blood pressure in healthy volunteers.
    Muller MD; Ahmad TA; Vargas Pelaez AF; Proctor DN; Bonavia AS; Luck JC; Maman SR; Ross AJ; Leuenberger UA; McQuillan PM
    J Appl Physiol (1985); 2017 Mar; 122(3):511-519. PubMed ID: 28035016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esmolol: effects on isoprenaline- and exercise-induced cardiovascular stimulation in conscious dogs.
    Fischer G; Grohs JG; Raberger G
    Can J Physiol Pharmacol; 1990 Oct; 68(10):1322-8. PubMed ID: 1981854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of esmolol for unstable angina pectoris.
    Wallis DE; Pope C; Littman WJ; Scanlon PJ
    Am J Cardiol; 1988 Nov; 62(16):1033-7. PubMed ID: 2903659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy.
    Mooss AN; Hilleman DE; Mohiuddin SM; Hunter CB
    Ann Pharmacother; 1994 Jun; 28(6):701-3. PubMed ID: 7919552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol.
    Barbier GH; Shettigar UR; Appunn DO
    Int J Clin Pharmacol Ther; 1995 Apr; 33(4):212-8. PubMed ID: 7620691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular and antiarrhythmic effects of esmolol in children.
    Trippel DL; Wiest DB; Gillette PC
    J Pediatr; 1991 Jul; 119(1 Pt 1):142-7. PubMed ID: 1676729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Esmolol, an ultrashort-acting, selective beta 1-adrenoceptor antagonist: pharmacodynamic and pharmacokinetic properties.
    Volz-Zang C; Eckrich B; Jahn P; Schneidrowski B; Schulte B; Palm D
    Eur J Clin Pharmacol; 1994; 46(5):399-404. PubMed ID: 7957532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics.
    Wiest D
    Clin Pharmacokinet; 1995 Mar; 28(3):190-202. PubMed ID: 7758250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of intravenous infusion of esmolol and propranolol on biventricular performance at rest and during exercise as assessed by quantitative radionuclide angiography.
    Iskandrian AS; Hakki AH; Laddu A; Steck J; Saunders R; Kane-Marsch S; Morganroth J
    Am J Cardiol; 1985 May; 55(11):1287-92. PubMed ID: 3993558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Esmolol hydrochloride: an ultrashort-acting, beta-adrenergic blocking agent.
    Angaran DM; Schultz NJ; Tschida VH
    Clin Pharm; 1986 Apr; 5(4):288-303. PubMed ID: 2871961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining the dose range for esmolol used in electroconvulsive therapy hemodynamic attenuation.
    Howie MB; Hiestand DC; Zvara DA; Kim PY; McSweeney TD; Coffman JA
    Anesth Analg; 1992 Nov; 75(5):805-10. PubMed ID: 1358003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time course of a new ultrashort-acting beta-adrenoceptor-blocking drug, ONO-1101: comparison with those of esmolol and propranolol by using the canine isolated, blood-perfused heart preparations.
    Motomura S; Hagihara A; Narumi Y; Hashimoto K
    J Cardiovasc Pharmacol; 1998 Mar; 31(3):431-40. PubMed ID: 9514189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled beta-receptor blockade with flestolol: a novel ultrashort-acting beta-blocker.
    Murthy VS; Hwang TF; Rosen LB; Gorczynski RJ
    J Cardiovasc Pharmacol; 1987 Jan; 9(1):72-8. PubMed ID: 2434798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of esmolol on airway function in patients with asthma.
    Sheppard D; DiStefano S; Byrd RC; Eschenbacher WL; Bell V; Steck J; Laddu A
    J Clin Pharmacol; 1986 Mar; 26(3):169-74. PubMed ID: 2870080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions of esmolol and adenosine in atrioventricular nodal-dependent supraventricular tachycardia: implication for the cellular mechanisms of adenosine.
    Chang KC; Lin YC; Chen JY; Chou HT; Hung JS
    Cardiology; 2002; 97(3):138-46. PubMed ID: 12077566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.